PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma

[frothmouth]

“PharmaEngine Inc. (TWO: 4162), a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. (Euronext: NANO), a clinical-stage nanomedicine company pioneering in novel approaches for local treatment of cancer, announced today that the companies had strengthened their collabor